QGEN logo

QIAGEN N.V.

QGENNYSE
πŸ† #842 by market capEarnings Nov 3US Equity
$42.65β–Ό $1.17 (βˆ’2.74%)
πŸŒ… Pre-market$42.15β–Ό 1.17%Regular close Β· extended-hours price shown
1hβ€”
24hβ–Ό 2.7%
7dβ–² 1.8%
14dβ–² 2.0%
30dβ–² 2.9%
1yβ–Ό 12.9%
🏦Market Cap
$8.80B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+4.8%
Slowing
πŸ“ŠGross Margin
62.6%
High
πŸ’΅FCF Margin
19.2%
Healthy
βš–οΈP/S Ratio
4.3x
Fair
Otter Score
65
Fair

Trading Snapshot

Day Range
$42.45 – $43.03
52-Week Range
$32.53 – $57.82
Volume
$3.28B
Avg Volume
$3.09B
Shares Outstanding
206.3M
Next Earnings
Sep 13, 2026

Fundamentals Snapshot

Annual Revenue
$2.09B
Last Q Revenue
$535M
P/E Ratio
22.6
P/S Ratio
4.3x
EPS (TTM)
$1.89
Dividend Yield
β€”

Why Investors Own QGEN

  • βœ“High-growth profile β€” revenue up +22.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 30% gross margin and 8% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$2.09Bβ–² +20.5% YoY
Gross Margin (TTM)
30.2%β–² +2.1% YoY
Operating Income (TTM)
$468Mβ–² +20.5% YoY
Free Cash Flow (TTM)
$165Mβ–² +20.5% YoY

About QIAGEN N.V.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
65/100

Analyst Price Target

β“˜
Average Target
$56.83
β–² +33.3% Upside
High Target$67.92
Low Target$43.49
Based on 14 analysts

Latest News & Updates